Please use the dropdown below to find out about EIA Kits available in the United States:
CanAg CEA EIA (RUO)
This product is available for Research Use Only and is not for use in diagnostic procedures.
Carcinoembryonic antigen (CEA) is a glycoprotein, which was first identified in patients with colonic carcinoma and in epithelial tumors of endodermal origin (gastrointestinal tract) by Gold and Freedman1. The CEA molecule is quite heterogeneous due to the carbohydrate contents (50-60%) and depending on the purification procedure employed. It is soluble in perchloric acid and has a molecular weight of about 175.000-200.000 Daltons2. Immunological and genetic characterization of CEA has identified a family of CEA-like molecules sharing common antigenic determinants. The most relevant CEA-like molecule is NCA (non-specific cross-reacting antigen) synthesized both by normal and pathological tissues. The problem of cross-reacting CEA-like molecules when assaying CEA is possible to overcome by the use of monoclonal antibodies. The Fujirebio Diagnostics CEA EIA is based on two mouse monoclonal antibodies against the Gold epitopes IV and V3, 4.
Download our CanAg CEA product information:
Product no: 401-85
- Gold P. and Freedman S. O. (1965) Specific carcinoembryonic antigens of the human digestive system. J. Exp Med 122: 467-481.
- Thompson J.A. and Zimmerman W. (1988) The carcinoembryonic antigen gene family: Structure, expression and evolution. Tumor Biol,; 9: 63-83.
- Börmer, O.P. (1992) Thesis “Immunoassays for Carcinoembryonic antigen, Specificity and Interferences”. ISBN 82-7633-014-2.
- Hammarström S. et al. (1989) Antigenic sites in carcinoembryonic antigen. Cancer Res 49: 4852-4858.